...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants
【24h】

Effect of palivizumab prophylaxis on subsequent recurrent wheezing in preterm infants

机译：预防帕利珠单抗对早产儿随后反复喘息的作用

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND OBJECTIVES: Palivizumab effectively prevents severe respiratory syncytial virus (RSV) disease in preterm infants. Our objective was to test whether palivizumab prophylaxis given to preterm infants during the first RSV season reduces the incidence of subsequent recurrent wheezing up to 3 years of life. METHODS: We conducted an observational prospective multicenter (52 registered hospitals in Japan) case-control study in preterm infants with a gestational age between 33 and 35 weeks followed for 3 years. During the 2007-2008 RSV season, the decision to administer palivizumab was made based on standard medical practice. In April 2008, 52 hospitals were recruited. Study participants were prospectively followed to the age of 3 years. Parents of study subjects reported the infants' physician's assessment of recurrent wheezing, used a report card and a novel mobile phone-based reporting system by using the Internet. The primary end point was the incidence of physician-diagnosed recurrent wheezing. RESULTS: Of 444 preterm infants enrolled, 349 received palivizumab during the first 6 months of life and 95 infants did not. Physiciandiagnosed recurrent wheezing was observed in 6.4% and 18.9% of infants in the treated and untreated groups, respectively (P , .001). This difference remained significant after adjustment for known risk factors of recurrent wheezing (P , .001). CONCLUSIONS: Palivizumab prophylaxis administered to preterm infants 33 to 35 weeks' gestational age is associated with a significantly lower incidence of recurrent wheezing during the first 3 years of life. Pediatrics 2013;132:811-818.
机译：背景与目的：帕利珠单抗可有效预防早产儿的严重呼吸道合胞病毒（RSV）疾病。我们的目标是测试在RSV的第一个季节对早产儿进行的帕利珠单抗预防是否可以减少随后复发性喘息的发生率，直至3岁。方法：我们对胎龄在33至35周之间的早产婴儿进行了观察性前瞻性多中心（日本52家注册医院）病例对照研究，随访了3年。在2007年至2008年的RSV季节中，帕利珠单抗的管理决定是基于标准的医学实践。 2008年4月，招募了52家医院。前瞻性地追踪了研究参与者至3岁的年龄。研究对象的父母报告了婴儿医师对反复喘息的评估，通过互联网使用了成绩单和新颖的基于手机的报告系统。主要终点是医生诊断的反复喘息的发生率。结果：在444名早产儿中，有349名在出生后头6个月接受了帕利珠单抗治疗，而95名婴儿则没有。在治疗组和未治疗组中，分别有6.4％和18.9％的婴儿观察到医生诊断的反复喘息（P，.001）。调整已知的复发性喘息危险因素后，这种差异仍然很显着（P ＜0.001）。结论：对胎龄33至35周的早产儿给予预防帕利珠单抗治疗与生命最初3年内反复喘息的发生率显着降低有关。儿科2013; 132：811-818。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号